Home Care Accreditors Secure Ongoing Medicare Seal
Published Date: 2/21/2025
Notice
Summary
The government has given the green light for the Accreditation Commission for Health Care Inc. (ACHC) to keep approving home health agencies that want to work with Medicare and Medicaid. This means home health agencies can continue getting certified through ACHC, helping them serve patients who rely on these programs. No big changes in timing or costs are expected, so everyone can keep doing their important work smoothly.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ACHC Accreditation Approval Continues
If you run a home health agency (HHA), the Accreditation Commission for Health Care (ACHC) is approved to continue accrediting HHAs that want to participate in the Medicare or Medicaid programs. This lets your agency keep seeking certification through ACHC so you can bill Medicare or Medicaid, and the notice says no big changes in timing or costs are expected.
Medicare/Medicaid Patients Maintain Access
If you have Medicare or Medicaid, home health agencies accredited by ACHC can continue to participate in those programs so you can keep getting home health services from ACHC‑accredited agencies. The notice confirms ACHC remains a recognized national accreditor for HHAs that wish to participate in Medicare or Medicaid.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10890 — Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model
Starting July 1, 2026, Medicare is updating the Increasing Organ Transplant Access (IOTA) Model to help kidney transplant hospitals do even better at getting more people transplanted and improving care quality. These changes affect hospitals involved in kidney transplants and aim to make the process smoother and more effective, with new payment rules that reward success. This update is part of a 6-year plan running through 2031 to save more lives and boost patient experience.
2026-10292 — Medicaid Program; Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Medicaid Practitioner Payments
This proposed rule changes how states can pay Medicaid managed care plans and certain doctors to make sure payments are fair, efficient, and encourage enough providers to offer quality care. It affects states, Medicaid managed care organizations, and targeted Medicaid practitioners, aiming to keep payments balanced and services available. Comments on these changes are open until July 21, 2026, so stakeholders have time to weigh in before it’s finalized.
2026-10050 — Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program
Starting in 2027, health insurance plans on federal and state marketplaces will see new rules to make coverage fairer and easier to use. These changes affect insurance companies, agents, and people buying plans, including new fees, penalties, and better protections for those with hardships. Expect updates on plan quality, dental coverage limits, and longer-term catastrophic plans, all aiming to keep your health coverage solid and affordable.
2026-07205 — Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges
This new rule will help Medicare, Medicaid, CHIP, and health plan companies share patient info more easily and speed up drug approval requests. It affects Medicare Advantage, Medicaid, CHIP, and health plans on federal exchanges, aiming to make care smoother and faster. These changes will start soon and could save time and money by cutting red tape.
2026-04797 — Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program; Correction
This document fixes some typos and technical mistakes in the Medicare and Medicaid payment rules for 2026. It affects doctors, healthcare providers, and anyone using Medicare Part B by clarifying payment policies and program requirements starting January 1, 2026. These corrections help make sure payments and coverage rules are clear and accurate, so everyone gets paid right and on time.
2026-04467 — Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program; Correction
This correction fixes some missing labels in important tables from the 2027 health insurance rules under the Affordable Care Act. It mainly affects insurance companies and people using marketplace plans by clarifying how risk and payments are calculated. These fixes take effect right away on March 6, 2026, ensuring everyone has clear info before the 2027 plan year starts.
Previous / Next Documents
Previous: 2025-02917 — AMG Comvest Senior Lending Fund and Comvest Credit Managers, LLC
AMG Comvest Senior Lending Fund and Comvest Credit Managers want permission to offer different types of shares with various fees and sales charges. This change affects investors in these funds by giving them more choices on how they invest and pay fees. The SEC will decide by March 13, 2025, unless someone asks for a hearing, and this could impact how much investors pay over time.
Next: 2025-02919 — Foreign-Trade Zone (FTZ) 49; Authorization of Production Activity; Merck, Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey
Merck, Sharp & Dohme LLC got the green light to make pharmaceutical products for research at their Rahway, New Jersey facility inside Foreign-Trade Zone 49. This means they can produce these products with special trade benefits, helping them save money and speed up their work. The approval was finalized on February 18, 2025, so they can start right away!